{"url_path":"/sec/anip/10-k/2026/item-15","section_key":"item-15","section_title":"Item 15 Exhibits and Financial Statement Schedules","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-02-27","source_url":"https://www.sec.gov/Archives/edgar/data/1023024/0001023024-26-000014-index.html","accession_number":"0001023024-26-000014","cik":"0001023024","ticker":"ANIP","issuer_name":"ANI PHARMACEUTICALS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1023024/0001023024-26-000014-index.html","primary_entity_key":"0001023024","primary_entity_name":"ANI PHARMACEUTICALS INC"},"word_count":1865,"has_tables":true,"body_markdown":"Item 15. Exhibits and Financial Statement Schedules\n\nDocuments filed as part of this report on Form 10-K:\n\n(a)Financial Statements:\n\nThe consolidated balance sheets of the Registrant as of December 31, 2025 and 2024, the related consolidated statements of operations, statements of other comprehensive income (loss), changes in stockholders’ equity, and cash flows for each of the years ended December 31, 2025, 2024, and 2023, the footnotes thereto, and the reports of EisnerAmper LLP, independent registered public accounting firm, are filed herewith.\n\n(b)Financial Statement Schedules:\n\nAll schedules have been omitted because they are not applicable or the required information is included in the consolidated financial statements or notes thereto.\n\n(c)Exhibits\n\nExhibits included or incorporated by reference herein: see Exhibit Index on page 146.\n\n145\n\n[Table of Contents](#id93db5ee702e4e9d8da25580f80f13e1_7)\n\nANI PHARMACEUTICALS, INC.\n\nEXHIBIT INDEX TO ANNUAL REPORT ON FORM 10-K\n\nFOR THE YEAR ENDED DECEMBER 31, 2025\n\nExhibit\n\nNo.\nExhibitMethod of Filing\n\n2.2\n[Agreement and Plan of Merger dated March 8, 2021 by and among ANI Pharmaceuticals, Inc., Nile Merger Sub LLC, Novitium Pharma LLC, Esjay LLC, Chali Properties, LLC, Chad Gassert, Muthusamy Shanmugam and Thorappadi Vijayaraj and Shareholder Representative Services LLC as the representative of the Company Members](https://www.sec.gov/Archives/edgar/data/1023024/000110465921033875/tm219108d2_ex2-1.htm)\n\nIncorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 9, 2021 (File No. 001-31812)\n\n2.3\n[Agreement and Plan of Merger dated June 21, 2024, by and among ANI Pharmaceuticals, Inc., ANIP Merger Sup INC. and Alimera Sciences, Inc. (1)](https://www.sec.gov/ix?doc=/Archives/edgar/data/1023024/000102302424000085/anip-20240630.htm)\n\nIncorporated by reference to Exhibit 2.1 to ANI's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 (File No. 001-31812)\n\n3.1\n[Certificate of Amendment of the Restated Certificate of Incorporation of BioSante Pharmaceuticals, Inc., dated as of July 17, 2013, Certificate of Amendment of the Restated Certificate of Incorporation of BioSante Pharmaceuticals, Inc., dated as of June 1, 2012, and Restated Certificate of Incorporation of BioSante Pharmaceuticals, Inc.](https://www.sec.gov/Archives/edgar/data/1023024/000114420413044160/v349735_ex3-1.htm)\n\nIncorporated by reference to Exhibit 3.1 to ANI’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2013 (File No. 001-31812).\n\n3.2\n[C](https://www.sec.gov/Archives/edgar/data/1023024/000102302425000056/exhibit31certificateofamen.htm)[ertificate of Amendment to the Restated Certificate of Incorporation of ANI Pharmaceuticals, Inc., dated May 22, 2025](https://www.sec.gov/Archives/edgar/data/1023024/000102302425000056/exhibit31certificateofamen.htm)\n\nIncorporated by reference to Exhibit 3.1 to ANI's Current Report on Form 8-K filed on May 22, 2025 (File No. 001-31812)\n\n3.3\n[Second Amended and Restated Bylaws of ANI Pharmaceuticals, Inc.](https://www.sec.gov/Archives/edgar/data/1023024/000110465923029038/tm238560d1_ex3-1.htm)\nIncorporated by reference to Exhibit 3.1 to ANI’s Current Report on Form 8-K as filed with the Securities and Exchange Commission on March 6, 2023 (File No. 001-31812)\n\n4.1\n[Description of Securities](exhibit41.htm)\nFiled herewith\n\n4.3\n[Indenture, dated as of August 13, 2024, between ANI Pharmaceuticals, Inc. and U.S. Bank Trust Company, National Association, as trustee](https://www.sec.gov/Archives/edgar/data/1023024/000095010324012144/dp216536_ex0401.htm)\nIncorporated by reference to Exhibit 4.1 to ANI's Current Report on Form 8-K filed on August 13, 2024 (File No. 001-31812)\n\n4.4\n[Form of Certificate representing the 2.25% Convertible Senior Notes due 2029 (included as Exhibit A to Exhibit 4.3)](https://www.sec.gov/Archives/edgar/data/1023024/000095010324012144/dp216536_ex0401.htm)\n\nIncorporated by reference to Exhibit 4.2 to ANI's Current Report on Form 8-K filed on August 13, 2024 (File No. 001-31812)\n\n10.1*\n\n[Employment Agreement, entered into by the Company and Stephen P. Carey](https://www.sec.gov/Archives/edgar/data/1023024/000110465920005962/tm205553d1_ex10-2.htm)\nIncorporated by reference to Exhibit 10.2 to ANI’s Current Report on Form 8-K filed January 22, 2020 (File No. 001-31812)\n\n10.2*\n\n[Employment Agreement between Nikhil Lalwani and ANI Pharmaceuticals, Inc., dated July 24, 2020](https://www.sec.gov/Archives/edgar/data/1023024/000110465920089648/tm2026323d1_ex10-1.htm)\nIncorporated by reference to Exhibit 10.1 to ANI’s Current Report on Form 8-K filed August 3, 2020 (File No. 001-31812)\n\n10.3*\n\n[Employment Agreement between Muthusamy Shanmugam and the Company, dated as of March 8, 2021 and effective as of November 19, 2021.](https://www.sec.gov/Archives/edgar/data/1023024/000110465921143748/tm2133555d1_ex10-3.htm)\n\nIncorporated by reference to Exhibit 10.3 to ANI’s Current Report on Form 8-K as filed with the Securities and Exchange Commission on November 26, 2021 (File No. 001-31812)\n\n146\n\n[Table of Contents](#id93db5ee702e4e9d8da25580f80f13e1_7)\n\nExhibit\n\nNo.\nExhibitMethod of Filing\n\n10.4*\n\n[Employment Agreement between and Christopher Mutz and the Company, dated February 10, 2021.](https://www.sec.gov/Archives/edgar/data/1023024/000102302422000004/anip-20211231ex1026e26af.htm)\nIncorporated by reference to Exhibit 10.26 to ANI’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (File No. 001-31812)\n\n10.5*\n\n[Employment Agreement between Ori Gutwerg and the Company, dated January 15, 2021.](https://www.sec.gov/Archives/edgar/data/1023024/000102302422000004/anip-20211231ex10272894a.htm)\nIncorporated by reference to Exhibit 10.27 to ANI’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (File No. 001-31812)\n\n10.6*\n\n[Employment Agreement between Meredith Cook and the Company, dated June 21, 2022.](https://www.sec.gov/Archives/edgar/data/1023024/000102302422000017/anip-20220630xex10d1.htm)\nIncorporated by reference to Exhibit 10.1 to ANI’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2022 (File No. 001-31812)\n\n10.7*\n\n[Amendment No. 1 to Employment Agreement between Stephen P. Carey and ANI Pharmaceuticals, Inc., dated October 27, 2025](https://www.sec.gov/Archives/edgar/data/1023024/000102302425000108/exhibit101amendmentno1toex.htm)\n\nIncorporated by reference to Exhibit 10.1 to ANI’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025 (File No. 001-31812)\n\n10.8*\n\n[Amendment No. 1 to Employment Agreement between Meredith Cook and ANI Pharmaceuticals, Inc., dated October 27, 2025](https://www.sec.gov/Archives/edgar/data/1023024/000102302425000108/exhibit102amendmentno1toex.htm)\n\nIncorporated by reference to Exhibit 10.2 to ANI’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025 (File No. 001-31812)\n\n10.9*\n\n[Amendment No. 1 to Employment Agreement between Ori Gutwerg and ANI Pharmaceuticals, Inc., dated October 27, 2025](https://www.sec.gov/Archives/edgar/data/1023024/000102302425000108/exhibit105amendmentno1toex.htm)\n\nIncorporated by reference to Exhibit 10.5 to ANI’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025 (File No. 001-31812)\n\n10.10*\n\n[Amendment No. 1 to Employment Agreement between Nikhil Lalwani and ANI Pharmaceuticals, Inc., dated October 27, 2025](https://www.sec.gov/Archives/edgar/data/1023024/000102302425000108/exhibit106amendmentno1toex.htm)\n\nIncorporated by reference to Exhibit 10.6 to ANI’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025 (File No. 001-31812)\n\n10.11*\n\n[Amendment No. 1 to Employment Agreement between Christopher Mutz and ANI Pharmaceuticals, Inc., dated October 27, 2025](https://www.sec.gov/Archives/edgar/data/1023024/000102302425000108/exhibit107amendmentno1toex.htm)\n\nIncorporated by reference to Exhibit 10.7 to ANI’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025 (File No. 001-31812)\n\n10.12*\n\n[Amendment No. 1 to Employment Agreement between Muthusamy Shanmugam and ANI Pharmaceuticals, Inc., dated October 27, 2025](https://www.sec.gov/Archives/edgar/data/1023024/000102302425000108/exhibit108amendmentno1toex.htm)\n\nIncorporated by reference to Exhibit 10.8 to ANI’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025 (File No. 001-31812)\n\n10.13\n[Asset Purchase Agreement, dated as of September 18, 2015, between Merck Sharp & Dohme B.V. and ANI Pharmaceuticals, Inc. (2)](https://www.sec.gov/Archives/edgar/data/1023024/000114420415062504/v421880_ex10-2.htm)\nIncorporated by reference to Exhibit 10.2 to ANI’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2015 (File No. 001-31812)\n\n10.14\n[Asset Purchase Agreement between Cranford Pharmaceuticals, LLC and ANI Pharmaceuticals, Inc. (2)](https://www.sec.gov/Archives/edgar/data/1023024/000114420416099268/v437620_ex10-2.htm)\nIncorporated by reference to Exhibit 10.2 to ANI’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2016 (File No. 001-31812)\n\n10.15*\n\n[Ame](https://www.sec.gov/Archives/edgar/data/1023024/000102302425000070/exhibit101anipespp.htm)[nded and Re](https://www.sec.gov/Archives/edgar/data/1023024/000102302425000070/exhibit101anipespp.htm)[stated](https://www.sec.gov/Archives/edgar/data/1023024/000102302425000070/exhibit101anipespp.htm)[ANI Pharmaceuticals, Inc. 2016 Employee Stock Purchase Plan](https://www.sec.gov/Archives/edgar/data/1023024/000102302425000070/exhibit101anipespp.htm)\n\nIncorporated by reference to Exhibit 10.1 to ANI's Form S-8 filed on July 11, 2025 (File No. 001-31812)\n\n10.16*\n\n[Amended and Restated 2022 Stock Incentive Plan](https://www.sec.gov/Archives/edgar/data/1023024/000102302425000069/exhibit101anipstockplan.htm)\nIncorporated by reference to Exhibit 10.1 to ANI's Form S-8 filed on July 11, 2025 (File No. 001-31812)\n\n147\n\n[Table of Contents](#id93db5ee702e4e9d8da25580f80f13e1_7)\n\nExhibit\n\nNo.\nExhibitMethod of Filing\n\n10.17*\n\n[ANI Pharmaceuticals, Inc. Amended and Restated 2022 Stock Incentive Plan Sub-Plan for U.K. Employees](https://www.sec.gov/Archives/edgar/data/1023024/000102302424000102/a104anipharmaceuticalsinca.htm)\n\nIncorporated by reference to Exhibit 10.4 to ANI's Quarterly report on Form 10-Q for the fiscal quarter ended September 30, 2024 (File No. 001-31812)\n\n10.18*\n\n[Inducement Stock Option Award Agreement, effective as of September 8, 2020, between ANI Pharmaceuticals, Inc. and Nikhil Lalwani](https://www.sec.gov/Archives/edgar/data/1023024/000102302420000008/anip-20200930ex1020d6792.htm)\nIncorporated by reference to Exhibit 10.2 to ANI’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2020 (File No. 001-31812)\n\n10.19*\n\n[ANI Pharmaceuticals, Inc. Executive Incentive Bonus Plan](https://www.sec.gov/Archives/edgar/data/1023024/000110465922028128/tm227815d1_ex10-1.htm)\nIncorporated by reference to Exhibit 10.1 to ANI’s Current Report on Form 8-K filed on February 28, 2022 (File No. 001-31812)\n\n10.20\n[Assignment and Technology Transfer Agreement between BioSante Pharmaceuticals, Inc. and Cold Genesys, Inc., dated as of November 15, 2010](https://www.sec.gov/Archives/edgar/data/1023024/000102302424000057/anip20240331-ex101.htm)\n\nIncorporated by reference to Exhibit 10.1 to ANI’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 (File No. 001-31812)\n\n10.21\n[Form of Capped Call Transaction Confirmation](https://www.sec.gov/Archives/edgar/data/1023024/000095010324012144/dp216536_ex1001.htm)\nIncorporated by reference to Exhibit 10.1 to ANI’s Current Report on Form 8-K filed on August 13, 2024 (File No. 001-31812)\n\n10.22†\n\n[Credit Agreement, dated as of August 13, 2024, among ANI Pharmaceuticals, Inc., ANIP Acquisition Company, the guarantors party thereto., JPMorgan Chase Bank, N.A., as administrative agent, and other financial institutions as lenders](https://www.sec.gov/Archives/edgar/data/1023024/000095010324012144/dp216536_ex1002.htm)\nIncorporated by reference to Exhibit 10.2 to ANI’s Current Report on Form 8-K filed on August 13, 2024 (File No. 001-31812)\n\n10.23\n[Contingent Value Rights Agreement dated September 16, 2024, by and between ANI Pharmaceuticals, Inc. and Continental Stock Transfer & Trust Company](https://www.sec.gov/Archives/edgar/data/1023024/000102302424000093/exhibit101contingentvaluer.htm)\n\nIncorporated by reference to Exhibit 10.1 to ANI’s Current Report on Form 8-K filed on September 20, 2024 (File No. 001-31812)\n\n10.24\n[Form of Indemnification Agreement](https://www.sec.gov/Archives/edgar/data/1023024/000102302424000026/anip-20231231xexx1034.htm)\n\nIncorporated by reference to Exhibit 10.34 to ANI’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (File No. 001-31812)\n\n19.1\n[ANI Pharmaceuticals, Inc. Insider Trading Policy](https://www.sec.gov/Archives/edgar/data/1023024/000102302425000015/exhibit191aniinsidertradin.htm)\nIncorporated by reference to Exhibit 19.1 to ANI’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (File No. 001-31812)\n\n21\n[List of subsidiaries](anip-20251231xexx21.htm)\nFiled herewith\n\n23.1\n[Consent of EisnerAmper LLP](anip-2025x1231xexx231.htm)\nFiled herewith\n\n31.1\n[Certification of Chief Executive Officer Pursuant to SEC Rule 13a-14](anip-20251231xexx311.htm)\nFiled herewith\n\n31.2\n[Certification of Chief Financial Officer Pursuant to SEC Rule 13a-14](anip-20251231xexx312.htm)\nFiled herewith\n\n32.1\n[Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Rule 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](anip-20251231xexx321.htm)\nFurnished herewith\n\n97.1\n[ANI Pharmaceuticals, Inc. Amended and Restated Clawback Policy](https://www.sec.gov/Archives/edgar/data/1023024/000102302424000026/anip-20231231xexx971.htm)\n\nIncorporated by reference to Exhibit 97.1 to ANI’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (File No. 001-31812)\n\n148\n\n[Table of Contents](#id93db5ee702e4e9d8da25580f80f13e1_7)\n\nExhibit\n\nNo.\nExhibitMethod of Filing\n\n101\nThe following financial information from this Annual Report on Form 10-K for the fiscal year ended December 31, 2025, formatted in Inline XBRL: (i) the audited consolidated Balance Sheets, (ii) the audited consolidated Statements of Operations, (iii) the audited consolidated Statements of Comprehensive Income, (iv) the audited consolidated Statements of Mezzanine Equity and Stockholders’ Equity; (v) the audited consolidated Statements of Cash Flows, and (vi) Notes to consolidated Financial Statements.\nFiled herewith\n\n104\nThe cover page from the Company Annual Report on Form 10-K for the year ended December 31, 2025 formatted in inline XBRL (included in Exhibit 101)\nFiled herewith\n\n____________________\n\n(1) All exhibits to this exhibit have been omitted pursuant to Item 601(b)(2) of Regulation S-K. ANI will furnish the omitted exhibits to the SEC upon request by the SEC.\n\n(2) Confidential treatment has been granted with respect to redacted portions of this document or certain information has been omitted from this exhibit in accordance with Regulation S-K Item 601(b)(10)(iv). The Company agrees to furnish supplementally a copy of any omitted information to the Securities and Exchange Commission upon its request.\n\n* Management contract or compensatory plan or arrangement required to be filed as an exhibit to this Annual Report on Form 10-K pursuant to Item 15(a).\n\n† Certain schedules and certain exhibits to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule or exhibit will be furnished supplementally to the SEC upon request; provided, however, that the parties may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any document so furnished."}